The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...

Across all products, Biogen's sales declined 7% to ... But that still topped calls for $430 million, according to FactSet. Overall, Biogen's MS drugs brought in $1.08 billion in sales, narrowly ...

Communications agency Pegasus was given a brief to create an engaging platform capable of improving the understanding of MS and one of Biogen’s products among MS professionals. The result was MS ...

Biogen, Inc. is a biopharmaceutical ... diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA ...

Amid declining demand for MS drugs and Spinraza, Biogen believes its new products, Leqembi for Alzheimer’s disease, Skyclarys for Friedreich’s ataxia and Zurzuvae for depression, have the ...

Biogen's stock underperformed in 2024 due to poor sales of Leqembi and declining multiple sclerosis revenues, despite efforts to diversify its pipeline. Leqembi's market struggles continue ...

Court cites lack of inventiveness and failure to meet reproducibility standards | Decision part of broader international litigation with mixed rulings | Generics still barred from selling products ...

Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether Biogen Inc. or Exact Sciences Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Biogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.

In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against other NASDAQ 100 stocks that Jim Cramer discussed recently. Jim Cramer, the host of Mad Money ...

Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers ...